Area of research
Electrical and Electronic Engineering · Astronomy and Astrophysics
Research interest
Research focused on Synteny and Apatinib, with related work in Cardiotoxicity, Crizotinib, Mendelian randomization. Notable publications include 'Comparative genomics reveals insights into avian genome evolution and adaptation', 'A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens', and 'Cardiotoxicity of 5‐fluorouracil and capecitabine in Chinese patients: a prospective study'.
Electronic Structure Engineering of PtZn Alloys to Accelerate Dehydrogenation for Efficient Ammonia Oxidation
Causal relationship between osteoporosis, bone mineral density, and osteonecrosis: a bidirectional two-sample Mendelian randomization study
Single Bolus r-SAK Before Primary PCI for ST-Segment–Elevation Myocardial Infarction
Hesperetin Attenuates T-2 Toxin-Induced Chondrocyte Injury by Inhibiting the p38 MAPK Signaling Pathway
Preparation and microwave absorption performance of SiC aerogel via sol-gel and carbonization reduction process
Burden of Ischemic Heart Disease Attributable to Lead Exposure and Projection of Trends: Insights from the Global Burden of Disease 2021 Study
Causal Relationship Between Osteoporosis, Bone Mineral Density, and Osteonecrosis: A Bidirectional Two-Sample Mendelian Randomization Study
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
Cardiotoxicity of 5‐fluorouracil and capecitabine in Chinese patients: a prospective study
Early presence of antiangiogenesis-related adverse events as a potential biomarker of antitumor efficacy in patients with metastatic gastric cancer treated with apatinib.
Comparative genomics reveals insights into avian genome evolution and adaptation
A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens.
A phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimens.